TRAWSFYNYDD THERAPEUTICS RECEIVES APPROVAL FOR THE FIRST PATIENT TRIAL OF TRX01, A ONCE-DAILY PROTEASE INHIBITORPROTEASE INHIBITOR FOR THE TREATMENT OF COVID 19

12 Feb 2024
www.prnewswire.com
Phase 1
ROCKVILLE, Md., Feb. 12, 2024 /PRNewswire/ -- Trawsfynydd Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to pioneering antiviral treatments for respiratory viral diseases, today announced of a first-in-man clinical trial of the novel best-in-class COVID-19 treatment, TRX01, an inhibitor targeting the SARS-CoV-2 viral main protease (3CL, Mpro).
"COVID-19 remains a significant global health concern, with SARS-CoV-2 infections posing a leading cause of mortality in the United States, especially among individuals aged 65 and above," stated C. David Pauza, PhD, CSO of Trawsfynydd Therapeutics. TRX01 was rationally designed as a best-in-class therapeutic, that does not require ritonavir co-administration, and represents a major advance in the field. "We are thrilled to proceed with clinical development of this novel COVID-19 therapy, which may increase the options for treating this deadly viral disease," Dr. Pauza added.
The Phase 1 clinical trial marks the first assessment of human safety, tolerability, and pharmacokinetics for TRX01.
Trawsfynydd Therapeutics, a biopharmaceutical company co-founded by Orbimed Advisors and Torrey Pines Investment, focuses on the discovery and development of best-in-class antiviral treatments for respiratory viral diseases. The company is utilizing a hybrid AI platform (Expert Systems Inc.) that leverages proprietary data of key partners, chem-bio platforms, knowledge, and expertise to choose highly valuable molecular mechanisms of pathology for precision design and to accelerate the execution of discovery and development of best-in-class and first-in-class therapies. The company's team of seasoned drug developers are using their capabilities and platforms to become a leader in developing novel breakthrough medicines that maximize the clinical benefit of treatments for respiratory viral diseases. Ongoing programs in Trawsfynydd are advancing clinical-stage assets for SARS-CoV-2 and influenza viral diseases. For more information, please visit www.trawsfynyddther.com.
Media Contact:
C. David Pauza, PhD
Chief Science Officer
[email protected]
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.